WWM
APLS

Wolff Wiese Magana’s Apellis Pharmaceuticals APLS Stock Holding History

Wolff Wiese Magana’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-147
Closed -$4.24K – 960
2024
Q3 		$4.24K Buy
+147
New +$5.44K ﹤0.01% 609

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Wolff Wiese Magana's APLS Position: Q4 2024 in Review

Wolff Wiese Magana sold out of Apellis Pharmaceuticals (APLS) in Q4 2024, closing a stake of 147 shares — an estimated $4.24K sold.

Wolff Wiese Magana first reported a position in APLS in Q3 2024 and held it in 1 quarter. The position peaked at $4.24K in Q3 2024. 260 funds tracked by Wall St. Rank hold APLS as of Q4 2024.

  • Wolff Wiese Magana reported no remaining Apellis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Wolff Wiese Magana sold 147 Apellis Pharmaceuticals shares in Q4 2024, an estimated $4.24K.
  • Wolff Wiese Magana first reported a position in Apellis Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Wolff Wiese Magana's Apellis Pharmaceuticals position peaked at $4.24K in Q3 2024.
  • 260 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2024.

Based on Wolff Wiese Magana's 13F filing for Q4 2024, filed 14 Jan 2025.